Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study

Elkind-Hirsch, Karen E.; Chappell, Neil; Shaler, Donna; Storment, John; Bellanger, Drake

doi:10.1016/j.fertnstert.2022.04.027

Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study

OBJECTIVE To study the efficacy and safety of the GLP-1 analog liraglutide 3 mg (LIRA 3 mg) vs. placebo (PL) for reduction of body weight (BW) and hyperandrogenism in women with obesity and polycystic ovary syndrome (PCOS). DESIGN Randomized, double-blind, placebo-controlled trial. SETTING Hospit…